Galux, an AI drug development startup, signed an agreement to conduct joint research for cancer drug development with LG Chem, the company said Monday.   Galux will design a lead compound for new cancer treatment with its AI technology, while LG Chem will handle the optimization of the lead compound and global nonclinical and clinical trials. Galux, established in 2020, recently introduced GaluxDesign, an antibody design method that the company explains rivals the performance of Google’s AlphaFold. The startup so far secured 26 billion won ($19.6 million) in funding from investors including LG Corp. (ICE SEOUL)

Fonte notizia: KOREA JOONGANG DAILY